Clinical Trials in Phoenix

Showing 8801-8820 of 16,646 trials

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061

We will need about 36 participants for this study. Volunteers might be able to participate if: * they have bad noninfectious keratitis * early treatments failed or were not well tolerated Participants will be in the study for about 22 weeks: * 4 weeks for tests to see if the study might be good for them * 12 weeks of treatment with Acthar gel * 4 weeks to wean off Acthar gel and follow-up with the doctor

Keratitis

Mallinckrodt36 participantsStarted Nov 2019

Phoenix, Arizona, United States • Glendale, California, United States • Newport Beach, California, United States +6 more locations

COMPLETEDPhase 3< 1 mile

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

NCT01339559

This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).

Epilepsy

UCB BIOSCIENCES, Inc.767 participantsStarted May 2011

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +181 more locations

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Find Trials by Condition in Phoenix

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Study of Octanorm Subcutaneous IG in Patients With PID

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL